Follicular Lymphoma Evaluation Index ( FLEX ): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapy-Reference-Cited by-同舟云学术

Follicular Lymphoma Evaluation Index ( FLEX ): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapy

Published:2020-09-16 Issue:12 Volume:95 Page:1503-1510
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Mir Farheen¹^ORCID,Mattiello Federico²,Grigg Andrew³,Herold Michael⁴,Hiddemann Wolfgang⁵,Marcus Robert⁶,Seymour John F.⁷,Bolen Christopher R.⁸,Knapp Andrea²,Nielsen Tina²,Casulo Carla⁹

Affiliation:

1. The Royal Marsden NHS Trust Foundation London UK

2. F. Hoffmann‐La Roche Ltd Basel Switzerland

3. Austin Hospital Melbourne Victoria Australia

4. HELIOS‐Klinikum Erfurt Erfurt Germany

5. University Hospital Munich Munich Germany

6. HCA Healthcare London UK

7. Peter MacCallum Cancer Centre Royal Melbourne Hospital and University of Melbourne Melbourne Victoria Australia

8. Genentech, Inc South San Francisco California USA

9. Wilmot Cancer Institute University of Rochester New York New York USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25973

Reference24 articles.

1. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

2. Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) investigation using individual data from 5453 patients on 13 trials;Casulo C;Blood,2017

3. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

4. High‐risk follicular lymphoma patients: identification and treatment;Luminari S;Eur J Oncol,2018

5. EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How Should We Risk Stratify and Tailor Therapy for Relapsed/Refractory Indolent Lymphoma?;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Age and lymphocyte/monocyte ratio as prognostic factors for autologous transplantation in the treatment of patients with follicular lymphoma;Journal of International Medical Research;2024-02

3. A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma;Hematological Oncology;2023-11-09

4. External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse;Clinical Lymphoma Myeloma and Leukemia;2023-09

5. EXABS-109-LYM Should We Use Prognostic Indices and/or Biomarkers to Guide Therapy in Follicular Lymphoma?;Clinical Lymphoma Myeloma and Leukemia;2023-09